Identification of cancer genes by mutational profiling of tumor genomes

FEBS Letters

Volumn 579, Issue 8, 2005, Pages 1884-1890

  Benvenuti, Silvia ^a   Arena, Sabrina ^a   Bardelli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer genome; Gene family; Mutational analysis; Oncogenomics; Tailored therapies

Indexed keywords

BCR ABL PROTEIN; CETUXIMAB; ERLOTINIB; GEFITINIB; GENOMIC DNA; GUANOSINE TRIPHOSPHATASE; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRASTUZUMAB;

BIOINFORMATICS; BREAST CANCER; CANCER; CANCER GENETICS; CARCINOGENESIS; CELL CONTACT; CELL CYCLE; CHROMOSOME 13; CHRONIC MYELOID LEUKEMIA; DRUG PROTEIN BINDING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 14844318078     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.02.015     Document Type: Short Survey

References (45)

1. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat. Med. 10 2004 789 799
2. B. Vogelstein, and K.W. Kinzler The multistep nature of cancer Trends Genet. 9 1993 138 141
3. A. Bardelli, and V.E. Velculescu Mutational analysis of gene families in human cancer Curr. Opin. Genet. Dev. 15 2005 5 12
4. P.A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M.R. Stratton A census of human cancer genes Nat. Rev. Cancer 4 2004 177 183
5. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal Mutations of the BRAF gene in human cancer Nature 2002
6. K.E. Bachman, P. Argani, Y. Samuels, N. Silliman, J. Ptak, S. Szabo, H. Konishi, B. Karakas, B.G. Blair, C. Lin, B.A. Peters, V.E. Velculescu, and B.H. Park The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol. Ther. 3 2004 772 775
7. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
8. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
9. R. Bernards, and R.A. Weinberg A progression puzzle Nature 418 2002 823
10. H.E. Varmus Form and function of retroviral proviruses Science 216 1982 812 820
11. Rous, P. (1979) A transmissible avian neoplasm. (Sarcoma of the common fowl) by Peyton Rous, M.D., Experimental Medicine for Sept. 1, 1910, vol. 12, pp. 696-705. J Exp Med 150, 738-753
12. B.G. Neel, W.S. Hayward, H.L. Robinson, J. Fang, and S.M. Astrin Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion Cell 23 1981 323 334
13. W.S. Hayward, B.G. Neel, and S.M. Astrin Activation of a cellular oncogene by promoter insertion in ALV-induced lymphoid leukosis Nature 290 1981 475 480
14. C. Shih, B.Z. Shilo, M.P. Goldfarb, A. Dannenberg, and R.A. Weinberg Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin Proc. Natl. Acad. Sci. USA 76 1979 5714 5718
15. T.G. Krontiris, and G.M. Cooper Transforming activity of human tumor DNAs Proc. Natl. Acad. Sci. USA 78 1981 1181 1184
16. L.F. Parada, C.J. Tabin, C. Shih, and R.A. Weinberg Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene Nature 297 1982 474 478
17. C.J. Tabin, S.M. Bradley, C.I. Bargmann, R.A. Weinberg, A.G. Papageorge, E.M. Scolnick, R. Dhar, D.R. Lowy, and E.H. Chang Mechanism of activation of a human oncogene Nature 300 1982 143 149
18. E.P. Reddy, R.K. Reynolds, E. Santos, and M. Barbacid A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene Nature 300 1982 149 152
19. B. Falini, and D.Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood 99 2002 409 426
20. J. Groffen, J.R. Stephenson, N. Heisterkamp, A. de Klein, C.R. Bartram, and G. Grosveld Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 Cell 36 1984 93 99
21. E. Shtivelman, B. Lifshitz, R.P. Gale, and E. Canaani Fused transcript of abl and bcr genes in chronic myelogenous leukaemia Nature 315 1985 550 554
22. H. Harris The analysis of malignancy by cell fusion: the position in 1988 Cancer Res. 48 1988 3302 3306
23. A.G. Knudson Jr. Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. USA 68 1971 820 823
24. E. Orye, M.J. Delbeke, and B. Vandenabeele Retinoblastoma and long arm delection of chromosome 3. Attempts to define the deleted segment Clin. Genet. 5 1974 457 464
25. U. Francke Retinoblastoma and chromosome 13 Birth Defects Orig. Artic. Ser. 12 1976 131 134
26. J. Kato, H. Matsushime, S.W. Hiebert, M.E. Ewen, and C.J. Sherr Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4 Genes Dev. 7 1993 331 342
27. A. Bardelli, D.W. Parsons, N. Silliman, J. Ptak, S. Szabo, S. Saha, S. Markowitz, J.K. Willson, G. Parmigiani, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Mutational analysis of the tyrosine kinome in colorectal cancers Science 300 2003 949
28. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 2002 934
29. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
30. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
31. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, and T. Mustelin Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
32. A.R. Forrest, T. Ravasi, D. Taylor, T. Huber, D.A. Hume, and S. Grimmond Phosphoregulators: protein kinases and protein phosphatases of mouse Genome Res. 13 2003 1443 1454
33. Z. Wang, D. Shen, D.W. Parsons, A. Bardelli, J. Sager, S. Szabo, J. Ptak, N. Silliman, B.A. Peters, M.S. van der Heijden, G. Parmigiani, H. Yan, T.L. Wang, G. Riggins, S.M. Powell, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Mutational analysis of the tyrosine phosphatome in colorectal cancers Science 304 2004 1164 1166
34. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
35. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
36. S.F. Huang, H.P. Liu, L.H. Li, Y.C. Ku, Y.N. Fu, H.Y. Tsai, Y.T. Chen, Y.F. Lin, W.C. Chang, H.P. Kuo, Y.C. Wu, Y.R. Chen, and S.F. Tsai High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin. Cancer Res. 10 2004 8195 8203
37. J. Marx Medicine. Why a new cancer drug works well, in some patients Science 304 2004 658 659
38. R.L. Strausberg, A.J. Simpson, L.J. Old, and G.J. Riggins Oncogenomics and the development of new cancer therapies Nature 429 2004 469 474
39. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
40. B.J. Druker Imatinib as a paradigm of targeted therapies Adv. Cancer Res. 91 2004 1 30
41. A.T. van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, S. Dimitrijevic, M. Martens, A. Webb, R. Sciot, M. Van Glabbeke, S. Silberman, and O.S. Nielsen Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 2001 1421 1423
42. S. Hirota, T. Nishida, K. Isozaki, M. Taniguchi, J. Nakamura, T. Okazaki, and Y. Kitamura Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours J. Pathol. 193 2001 505 510
43. B.P. Rubin, S. Singer, C. Tsao, A. Duensing, M.L. Lux, R. Ruiz, M.K. Hibbard, C.J. Chen, S. Xiao, D.A. Tuveson, G.D. Demetri, C.D. Fletcher, and J.A. Fletcher KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res. 61 2001 8118 8121
44. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, H. Joensuu, L.S. McGreevey, C.J. Chen, A.D. Van den Abbeele, B.J. Druker, B. Kiese, B. Eisenberg, P.J. Roberts, S. Singer, C.D. Fletcher, S. Silberman, S. Dimitrijevic, and J.A. Fletcher Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J. Clin. Oncol. 21 2003 4342 4349
45. B. Leyland-Jones Trastuzumab: hopes and realities Lancet Oncol. 3 2002 137 144